Den Otter W, Hill F W, Klein W R, Koten J W, Steerenberg P A, De Mulder P H, Rhode C, Stewart R, Faber J A, Ruitenberg E J
Department of Functional Morphology, Faculty of Veterinary Medicine, Utrecht, The Netherlands.
Cancer Immunol Immunother. 1995 Jul;41(1):10-4. doi: 10.1007/BF01788954.
We have tested the therapeutic potency of peritumorally injected low doses of interleukin-2 (IL-2). Seventy tumours of the bovine ocular squamous-cell carcinoma (BOSCC), 1-3 cm in diameter, were treated with 5000, 20,000 or 200,000 U IL-2 from Eurocetus (Chiron) to find the optimal dose for treatment. Injections were given peritumorally on Monday to Friday on 2 consecutive weeks. The size of the tumours was measured before treatment and 1, 3, 4, 9 and 20 months after treatment. After 9 months complete regression was observed in 89% of the tumours treated with 5000 U IL-2, 80% treated with 20,000 U and 67% treated with 200,000 U. After 20 months, there was complete regression of 35%, 31% and 67% of the tumours respectively. The 9- and 20-month results of the 200,000-U treatment are significantly better than those of the 5000-U and 20,000-U treatments taken together. This protocol may be useful to treat advanced inoperable tumours (e.g. of the nasopharynx or skin) of human patients.
我们已经测试了瘤周注射低剂量白细胞介素-2（IL-2）的治疗效果。用来自欧洲赛特斯公司（奇龙公司）的5000、20000或200000单位IL-2对70个直径为1 - 3厘米的牛眼鳞状细胞癌（BOSCC）肿瘤进行治疗，以找到最佳治疗剂量。在连续两周的周一至周五进行瘤周注射。在治疗前以及治疗后1、3、4、9和20个月测量肿瘤大小。9个月后，接受5000单位IL-2治疗的肿瘤中89%出现完全消退，接受20000单位治疗的为80%，接受200000单位治疗的为67%。20个月后，肿瘤的完全消退率分别为35%、31%和67%。200000单位治疗组9个月和20个月的结果明显优于5000单位和20000单位治疗组结果之和。该方案可能对治疗人类患者的晚期不可手术肿瘤（如鼻咽癌或皮肤癌）有用。
